GlassScriptPhysician profile
Michael R Sorrell
NPI 1528069887
$16,382.39
in general payments reported to CMS, 2019-2025
60 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,455 · 2020: $2,779 · 2021: $4,352 · 2022: $3,303 · 2023: $2,086 · 2024: $1,408.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,389 · Education: $105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,388.57 |
| Education | $104.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,591.86 | 2020-2024 | Qulipta, Ubrelvy, Botox |
| Ucb, INC. | $928.09 | 2019-2024 | Briviact, Nayzilam |
| Acadia Pharmaceuticals INC | $826.08 | 2019-2024 | Nuplazid |
| Teva Pharmaceuticals USA, INC. | $796.77 | 2019-2024 | |
| Allergan, INC. | $783.86 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $687.21 | 2019-2022 | |
| Lilly USA, LLC | $610.49 | 2019-2024 | Emgality, Reyvow, Amyvid |
| Biogen, INC. | $581.57 | 2019-2022 | |
| Genzyme Corporation | $576.84 | 2019-2022 | |
| Emd Serono, INC. | $544.81 | 2019-2024 | Mavenclad |
| Amgen INC. | $494.09 | 2019-2023 | Aimovig |
| Neurocrine Biosciences, INC. | $480.70 | 2020-2024 | Ingrezza, Ongentys |
| Csl Behring | $468.27 | 2019-2024 | Hizentra |
| Pfizer INC. | $451.51 | 2019-2024 | |
| Sk Life Science, INC. | $390.74 | 2020-2024 |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Sorrell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.